Risk factors and clinical outcomes of post-gastrectomy sarcopenia newly developed after curative resection for gastric cancer

Abstract

66%, P < .05) The latest clinical trial data investigating novel therapies in HER2-positive gastric or gastroesophageal junction adenocarcinomas (pre 43%, post 48%, P¼0.447) The latest guideline recommendations regarding HER2-directed therapies in colorectal cancer (pre 39%, post 67%, P < .001). As a result of the education, 34% of the oncologists had a measurable improvement in confidence in their understanding of the potential therapeutic role of emerging HER2-directed therapies in the management of gastric and colorectal cancer and an average positive confidence shift of 14.5%. Conclusions: This study demonstrated the effectiveness of an online educational activity consisting of 5 expert commentaries, sequentially linked totaling up to 60 minutes of presentations, on improving the knowledge and confidence of oncologists regarding the most recent HER2 testing recommendations and the latest clinical trial data for new and emerging therapies in the HER2-positive gastric cancer and colorectal cancer setting.